Marcain

Bupivacaine, the active ingredient in Marcain, is a local anesthetic (amide type) presented as a sterile injectable solution for epidural and infiltration use. It provides long‑lasting nerve block for surgical anesthesia and postoperative analgesia in adult patients. The drug’s high potency and extended duration make it suitable for procedures requiring profound sensory blockade while preserving motor function when used at appropriate concentrations.

GNH USA supplies Marcain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures consistent quality and regulatory compliance across all shipments.

Marcain (bupivacaine) is employed in the management of pain and anesthesia across several clinical contexts. - Surgical anesthesia: Provides dense sensory and motor block for intra‑operative pain control during various surgeries. - Epidural analgesia: Delivers continuous pain relief for labor, postoperative recovery, or chronic pain via epidural catheter. - Infiltration anesthesia: Allows localized numbness for minor surgical or diagnostic procedures when injected directly into tissue.

Bupivacaine may be associated with a range of adverse reactions, varying from mild to severe. Common Side Effects: - Hypotension: transient drop in blood pressure after injection. - Dizziness or light‑headedness: feeling of imbalance. - Injection site pain: mild discomfort at the infiltration site. Serious or Rare Side Effects: - Cardiotoxicity: arrhythmias or cardiac arrest. - Central nervous system toxicity: seizures or loss of consciousness. - Allergic reactions: urticaria, bronchospasm, or anaphylaxis.

When using Marcain, clinicians should observe specific safety measures to minimize risk. - Assess cardiac function: evaluate baseline ECG and monitor for arrhythmias during administration. - Use lowest effective concentration: limit dose to reduce systemic toxicity. - Avoid intravascular injection: aspirate before injection and observe for signs of systemic absorption. - Caution in patients with hepatic impairment: reduced metabolism may prolong effect. - Monitor for CNS signs: watch for tinnitus, metallic taste, or seizures. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bupivacaine can interact with other agents, altering its safety profile. Major Interactions (Avoid): - Class I antiarrhythmic drugs (e.g., quinidine, procainamide): increase risk of cardiotoxicity. - Beta‑blockers (e.g., propranolol): potentiate bradycardia and hypotension. - General anesthetics (e.g., halothane, sevoflurane): synergistic CNS depression. Moderate Interactions (Monitor Closely): - Lidocaine: additive local anesthetic effect may raise systemic toxicity. - Epinephrine‑containing solutions: may modify absorption rate and prolong block. - Other local anesthetics: concurrent use can increase total local anesthetic load.